In breast cancer, high concentrations of TNF-α can activate receptors and trigger a potent and persistent activation of NFқB signaling [48,49], epithelial-to-mesenchymal transition [50], and continuous release of diverse chemokines, including CCL2 and CCL5 [51]. Here, CCL2 is linked to breast carcinoma.